P. Partanen

发表

Increased release of tenascin in tear fluid after photorefractive keratectomy

T. Tervo, K. Tervo, M. Vesaluoma, 1995, Graefe's Archive for Clinical and Experimental Ophthalmology.

Cellular fibronectin in serum and plasma: a potential new tumour marker?

C. Haglund, E. Vahtera, S. Ylätupa, 1995, British Journal of Cancer.

Five guaiac-based tests for occult blood in faeces compared in vitro and in vivo.

H. Adlercreutz, K. Liewendahl, P. Partanen, 1984, Scandinavian journal of clinical and laboratory investigation.

Sensitivity of in situ hybridization techniques using biotin- and 35S-labeled human papillomavirus (HPV) DNA probes.

S. Syrjänen, K. Syrjänen, P. Partanen, 1988, Journal of virological methods.

Synthetic env gp41 peptide as a sensitive and specific diagnostic reagent in different stages of human immunodeficiency virus type 1 infection

A. Vaheri, A. Närvänen, M. Korkolainen, 1988, Journal of medical virology.

Screening test for rheumatic diseases: a combined enzyme immunoassay of rheumatoid factors and antibodies to DNA and extractable nuclear antigens.

P. Kurki, T. Helve, P. Partanen, 1987, Journal of clinical pathology.

Screening testforrheumatic diseases: acombined enzyme immunoassay ofrheumatoid factors and antibodies toDNA andextractable nuclear antigens

P. Partanen, I. T. Helve, 1987 .

antigens . and extractable nuclear factors and antibodies to DNA immunoassay of rheumatoid diseases : a combined enzyme Screening test for rheumatic

P. Kurki, P. Partanen, M. Gripenberg, 2022 .

Identification of antigenic components of Toxoplasma gondii by an immunoblotting technique

P. Leinikki, J. Suni, E. Forsblom, 1983, FEBS letters.

Screening of colorectal tumours using an improved faecal occult blood test. Quantitative aspects.

R. Paasivuo, P. Partanen, I. Häkkinen, 1988, Gut.

Increased release of immunoreactive calcitonin gene-related peptide (CGRP) in tears after excimer laser keratectomy.

T. Tervo, S. Ylätupa, P. Mertaniemi, 1995, Experimental eye research.

Enzyme immunoassay for quantification of tenascin in biologic samples.

C. Haglund, S. Ylätupa, P. Mertaniemi, 1995, Clinical biochemistry.

Tear fluid cellular fibronectin levels after photorefractive keratectomy.

T. Tervo, T. Virtanen, S. Ylätupa, 1995, Journal of refractive surgery.

Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA.

C. Haglund, P. Mertaniemi, P. Partanen, 1997, British Journal of Cancer.

An improved method for quantification of extra domain A-containing cellular fibronectin (EDAcFN) in different body fluids.

C. Haglund, S. Ylätupa, P. Mertaniemi, 1995, Clinica chimica acta; international journal of clinical chemistry.

Competitive enzyme immunoassay for quantification of the cellular form of fibronectin (EDAcFN) in blood samples.

C. Haglund, I. Virtanen, S. Ylätupa, 1993, Journal of immunological methods.

Biologically active domain in somatomedin-binding protein.

R. Koistinen, H. Bohn, M. Huhtala, 1986, Biochemical and biophysical research communications.

Immunoblot analysis of Toxoplasma gondii antigens by human immunoglobulins G, M, and A antibodies at different stages of infection

R. Paasivuo, P. Partanen, P. Leinikki, 1984, Journal of clinical microbiology.

A monoclonal antibody against a synthetic peptide reveals common structures among spectrins and α‐actinin

A. Närvänen, V. Wasenius, I. Virtanen, 1987 .

Selective reactivity of antibodies to human immunoglobulins G, M, and A with rubella virus proteins

A. Vaheri, J. Suni, P. Partanen, 1985, Journal of clinical microbiology.

Immunological detection of faecal occult blood in colorectal cancer.

H. Adlercreutz, K. Liewendahl, P. Partanen, 1984, British Journal of Cancer.

Mutascreen, an automated bacterial mutagenicity assay.

H. Vainio, M. Sorsa, K. Falck, 1985, Mutation research.

Molecular and antigenic characteristics and synthesis of rubella virus structural proteins.

A. Vaheri, R. Pettersson, L. Kääriäinen, 1985, Reviews of infectious diseases.

Highly immunoreactive antigenic site in a hydrophobic domain of HIV-1 gp41 which remains undetectable with conventional immunochemical methods.

A. Vaheri, A. Närvänen, M. Korkolainen, 1988, AIDS.

Gastric cancer associated structure in mucus glycoproteins shown as a clinically useful marker.

P. Sipponen, T. Nevalainen, R. Paasivuo, 1991, Gut.